Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smartphone light sensor may spot when an irregular heartbeat fixes itself

NCT ID NCT07752940

Disease control Sponsor: Ziekenhuis Oost-Limburg Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This trial tests whether a smartphone app that uses light to measure heart rhythm can reliably detect when atrial fibrillation (AF) spontaneously returns to a normal heartbeat. About 200 adults with AF scheduled for an electrical cardioversion will either receive standard care or use the app twice daily for a week before the procedure. The goal is to see if this simple home monitoring can catch a natural recovery and prevent an unnecessary hospital visit, while also tracking symptoms and long-term rhythm outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Smartphone-based PPG monitoring using the FibriCheck application
What this could lead to
If successful, this approach could let some people with atrial fibrillation avoid an unnecessary hospital procedure by detecting when their heart rhythm has already returned to normal.
What could go wrong
The monitoring is intermittent and app-guided, so it may miss brief episodes of normal rhythm. The trial is relatively small and early, and results may not apply to all patients with atrial fibrillation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Provide signed and dated informed consent * Males or females aged ≥ 18 years * Diagnosis of atrial fibrillation based on ECG in medical history * Patient in atrial fibrillation when planned for electrical cardioversion as evidenced by an ECG * In possession of a smartphone * Being able and having the time to perform heart rhythm measurement using the FibriCheck application at home Exclusion Criteria: * Cardiac implantable devices such as pacemakers, CRT's or ICD's. * No access to a smartphone or unable to perform PPG measurements independently. * Active follow-up in Fibricheck care pathways

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation (AF) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation (AF)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospitals Leuven

    Leuven, Vlaams-Brabant, 3000, Belgium

  • Ziekenhuis Oost Limburg

    Genk, Limburg, 3600, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.